Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LAP3 | P28838 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leu-Leu SCHEMBL11140120 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL29401942 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL18774992 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL6044006 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL235250 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL13737576 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL30771444 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL29400696 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| SCHEMBL2722888 | 0.96 | ALDH1A1 (0.56) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| SCHEMBL1019805 | 0.96 | ALDH1A1 (0.56) | ALDH1A1MAPTSLC7A5MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119861198-A | Plasma metabolic marker combinations for distinguishing early lung cancer from pneumonia | 哈尔滨脉图精准技术有限公司 | 2025-04-22 | — | — | CN | claimed |
| US-20240400468-A1 | Bionutritional Compositions for Plants and Soils | ENVIROKURE, INCORPORATED (US) | 2024-12-05 | — | — | US | claimed |
| CN-118465125-A | Metabolic marker composition for gastric cancer diagnosis and screening method and application thereof | 哈尔滨脉图精准技术有限公司 | 2024-08-09 | — | — | CN | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| WO-2023009636-A1 | BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS | ENVIROKURE, INCORPORATED (US) | 2023-02-02 | — | — | WO | claimed |
| CN-113156096-A | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | claimed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | claimed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| EP-3242588-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2017-11-15 | — | — | EP | claimed |
| WO-2016151372-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA AND METABOLIC SYNDROME | MOHAN M ALAPATI (IN) | 2016-09-29 | — | — | WO | claimed |
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC | 2016-07-14 | — | — | US | claimed |
| WO-2016112337-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2016-07-14 | — | — | WO | claimed |
| EP-0910624-B1 | PROCESS FOR PRODUCING AND MULTIPLYING LYMPHOCYTES | ALBERT WINFRIED DR (DE) | 2004-09-22 | — | — | EP | claimed |
| EP-0286171-B1 | DIPEPTIDASE, ITS ISOLATION FROM LACTIC ACID BACTERIA, ANTIBODIES AGAINST THE DIPEPTIDASE, THE USE OF THE DIPEPTIDASE AND OF THE ANTIBODIES AGAINST IT | CAMPINA MELKUNIE B.V. (NL) | 1993-03-31 | — | — | EP | claimed |
| US-4888284-A | EXTRACTION USING ION EXCHANGE COLUMN CHROMATOGRAPHY | RIJKSUNIVERSITEIT TE GRONINGEN (NL) | 1989-12-19 | — | — | US | claimed |
| EP-0286171-A1 | Dipeptidase, its isolation from lactic acid bacteria, antibodies against the dipeptidase, the use of the dipeptidase and of the antibodies against it | CAMPINA MELKUNIE B.V. (NL) | 1988-10-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | FABP3, APOB, CAD | ALDH1A1 493/4885MAPT 2089/4885SLC7A5 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.